Breaking Finance News

KeyBanc Capital Markets downgraded Quintiles Transnational (NYSE:Q) from Overweight to Sector Weight in a statement released earlier today.

Showing a price of $102.79, Quintiles Transnational (NYSE:Q) traded 3.94% higher on the day. The last stock close price is up 16.97% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.02% over the date range. Quintiles Transnational has recorded a 50-day average of $97.06 and a two hundred day average of $90.20. Volume of trade was up over the average, with 3,206,995 shares of Q changing hands over the typical 2,038,300

KeyBanc Capital Markets has downgraded Quintiles Transnational (NYSE:Q) from Overweight to Sector Weight in a report released on 11/13/2017.

Previously on 10/27/2017, Barclays Capital released a statement on Quintiles Transnational (NYSE:Q) upped the target price from $100.00 to $120.00. At the time, this suggested an upside of 0.12%.

See Chart Below

Quintiles Transnational (NYSE:Q)

Quintiles Transnational has one year low of $70.10 and a one year high of $106.65 with a price-earnings ratio of 305.80 and has a market cap of $0.

In addition to KeyBanc Capital Markets reporting its stock price target, a total of 15 brokers have released a report on Quintiles Transnational. The 12-month price target is $76.50 with 8 brokerages rating the stock a strong buy, 9 equity analysts rating the company a buy, two equity analysts rating the company a hold, zero analysts rating the company a underperform, and lastly zero firms rating the stock a sell.

About Quintiles Transnational (NYSE:Q)

IQVIA Holdings Inc., formerly Quintiles IMS Holdings, Inc., provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services. The Research & Development Solutions segment provides biopharmaceutical development services. It offers project management and clinical monitoring, clinical trial support services, Q2 solutions, and strategic planning and design. The Integrated Engagement Services segment offerings include healthcare provider engagement services, patient engagement services, and scientific strategy and medical affairs services. The Company has its operations in the Americas, Europe and Africa, and the Asia-Pacific.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.